Monitoring of Isothermal Crystallization and Time-Temperature Transformation of Amorphous Felodipine: The Time-Domain Nuclear Magnetic Resonance Method

被引：0

作者：

Pajzderska, A. ^{[1
]}

Gonzalez, M. A. ^{[2
]}

Jarek, M. ^{[3
]}

Wasicki, J. ^{[1
]}

机构：

[1] Adam Mickiewicz Univ, Fac Phys, Uniwersytetu Poznanskiego 2, PL-61614 Poznan, Poland

[2] Inst Laue Langevin, 71 Ave Martyrs, Grenoble, France

[3] Adam Mickiewicz Univ, NanoBiomed Ctr, Wszechnicy Piastowskiej 3, Poznan, Poland

来源：

AAPS PHARMSCITECH | 2024年 / 25卷 / 07期

关键词：

physical stability; TTT diagram; recrystallization; relaxometry; time-domain NMR; DIFFUSIONLESS CRYSTAL-GROWTH; PHYSICAL STABILITY; SURFACE CRYSTALLIZATION; SOLUBILITY ADVANTAGE; MOLECULAR MOBILITY; DYNAMICS; PHARMACEUTICALS; GLASS; INDOMETHACIN; KINETICS;

D O I：

10.1208/s12249-024-02919-2

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The isothermal crystallization process of felodipine has been investigated using the time-domain Nuclear Magnetic Resonance (NMR) method for amorphous bulk and ground samples. The obtained induction and crystallization times were then used to construct the time-temperature-transformation (TTT) diagram, both above and below the glass transition temperature (Tg). The Nose temperature was found equal to 363 K. Furthermore, the dynamics of crystalline and amorphous felodipine were compared across varying temperatures. Molecular dynamics simulations were also employed to explore the hydrogen-bond interactions and dynamic properties of both systems.

引用

页数：12

共 54 条

[1] Calcium-antagonist drugs [J].

Abernethy, DR ;

Schwartz, JB .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (19) :1447-1457

[2]

Allen M.P., 2002, COMPUTER SIMULATION

[3] A THEORETICAL BASIS FOR A BIOPHARMACEUTIC DRUG CLASSIFICATION - THE CORRELATION OF IN-VITRO DRUG PRODUCT DISSOLUTION AND IN-VIVO BIOAVAILABILITY [J].

AMIDON, GL ;

LENNERNAS, H ;

SHAH, VP ;

CRISON, JR .

PHARMACEUTICAL RESEARCH, 1995, 12 (03) :413-420

[4] Effects of sorbed water on the crystallization of indomethacin from the amorphous state [J].

Andronis, V ;

Yoshioka, M ;

Zografi, G .

JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (03) :346-351

[5]

[Anonymous], 2009, Materials Studio Modelling Environment

[6] Integrated modeling program, applied chemical theory (IMPACT) [J].

Banks, JL ;

Beard, HS ;

Cao, YX ;

Cho, AE ;

Damm, W ;

Farid, R ;

Felts, AK ;

Halgren, TA ;

Mainz, DT ;

Maple, JR ;

Murphy, R ;

Philipp, DM ;

Repasky, MP ;

Zhang, LY ;

Berne, BJ ;

Friesner, RA ;

Gallicchio, E ;

Levy, RM .

JOURNAL OF COMPUTATIONAL CHEMISTRY, 2005, 26 (16) :1752-1780

[7] Molecular modelling and simulation of fusion-based amorphous drug dispersions in polymer/plasticizer blends [J].

Barmpalexis, Panagiotis ;

Karagianni, Anna ;

Katopodis, Konstantinos ;

Vardaka, Elisavet ;

Kachrimanis, Kyriakos .

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 130 :260-268

[8] Local Mobility in Amorphous Pharmaceuticals-Characterization and Implications on Stability [J].

Bhattacharya, Sisir ;

Suryanarayanan, Raj .

JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 98 (09) :2935-2953

[9] Glass Forming Ability of Amorphous Drugs Investigated by Continuous Cooling and Isothermal Transformation [J].

Blaabjerg, Lasse I. ;

Lindenberg, Eleanor ;

Lobmann, Korbinian ;

Grohganz, Holger ;

Rades, Thomas .

MOLECULAR PHARMACEUTICS, 2016, 13 (09) :3318-3325

[10] RELAXATION EFFECTS IN NUCLEAR MAGNETIC RESONANCE ABSORPTION [J].

BLOEMBERGEN, N ;

PURCELL, EM ;

POUND, RV .

PHYSICAL REVIEW, 1948, 73 (07) :679-712

← 1 2 3 4 5 6 →